EU/3/19/2227: Orphan designation for the treatment of tenosynovial giant cell tumour, localised and diffuse type
2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one
Table of contents
Overview
On 16 December 2019, orphan designation EU/3/19/2227 was granted by the European Commission to Pharma Gateway AB, Sweden, for 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (also known as DCC-3014) for the treatment of tenosynovial giant cell tumour, localised and diffuse type.
The sponsorship was transferred to Deciphera Pharmaceuticals (Netherlands) B.V., Netherlands, in July 2020.
The sponsor’s address was updated in August 2021.
Key facts
Active substance |
2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one
|
Intended use |
Treatment of tenosynovial giant cell tumour, localised and diffuse type
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2227
|
Date of designation |
16/12/2019
|
Sponsor |
Deciphera Pharmaceuticals (Netherlands) B.V.
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: